Trial Profile
Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors AbbVie
- 21 Nov 2018 Planned End Date changed from 31 Oct 2019 to 21 Nov 2018.
- 21 Nov 2018 Planned primary completion date changed from 31 Oct 2019 to 21 Nov 2018.
- 21 Nov 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.